A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030) \u2013 ClinicalTrials.gov<\/a>
NCT03449147<\/p>\n\n\n\nPublications<\/strong>:
McGarvey LP, Birring SS, Morice AH, Dicpinigaitis PV, Pavord ID, Schelfhout J, Nguyen AM, Li Q, Tzontcheva A, Iskold B, Green SA, Rosa C, Muccino DR, Smith JA; COUGH-1 and COUGH-2 Investigators. Efficacy and safety of gefapixant, a P2X(3) receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Lancet. 2022 Mar 5;399(10328):909-923. doi: 10.1016\/S0140-6736(21)02348-5.<\/p>\n\n\n\nCH-OGM-00002, 07\/2024<\/sup><\/p>\n","protected":false},"excerpt":{"rendered":"Publication of clinical trial results The information given below and the relevant links to the clinical data fulfil the requirements of Articles 71-73 of the Ordinance on Therapeutic Products (Therapeutic Products Ordinance, TPO). They supplement the information published in association with the Swiss marketing authorisation for the medicinal product. LYFNUA\u00ae Lyfnua\u00ae (Gefapixant), film-coated tablets, 45 […]<\/p>\n","protected":false},"author":282,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"editor_notices":[],"footnotes":""},"class_list":["post-5880","page","type-page","status-publish","hentry"],"yoast_head":"\n
Lyfnua - Publication of clinical trial results - msd.ch<\/title>\n<meta name=\"description\" content=\"Publication of clinical trial results for Lyfnua\u00ae (gefapixant), which was approved by Swissmedic on May 24, 2022.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.msd.ch\/en\/lyfnua-publication-of-clinical-trial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lyfnua - Publication of clinical trial results - msd.ch\" \/>\n<meta property=\"og:description\" content=\"Publication of clinical trial results for Lyfnua\u00ae (gefapixant), which was approved by Swissmedic on May 24, 2022.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.msd.ch\/en\/lyfnua-publication-of-clinical-trial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"msd.ch\" \/>\n<meta property=\"article:modified_time\" content=\"2024-07-16T05:21:01+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.msd.ch\/en\/lyfnua-publication-of-clinical-trial-results\/\",\"url\":\"https:\/\/www.msd.ch\/en\/lyfnua-publication-of-clinical-trial-results\/\",\"name\":\"Lyfnua - Publication of clinical trial results - msd.ch\",\"isPartOf\":{\"@id\":\"https:\/\/www.msd.ch\/en\/#website\"},\"datePublished\":\"2022-08-24T05:22:26+00:00\",\"dateModified\":\"2024-07-16T05:21:01+00:00\",\"description\":\"Publication of clinical trial results for Lyfnua\u00ae (gefapixant), which was approved by Swissmedic on May 24, 2022.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.msd.ch\/en\/lyfnua-publication-of-clinical-trial-results\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.msd.ch\/en\/#website\",\"url\":\"https:\/\/www.msd.ch\/en\/\",\"name\":\"msd.ch\",\"description\":\"MSD researches and develops medicines and vaccines to save lives and improve patients' health. In Switzerland, 1000 employees in Lucerne and Zurich are dedicated to this.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.msd.ch\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lyfnua - Publication of clinical trial results - msd.ch","description":"Publication of clinical trial results for Lyfnua\u00ae (gefapixant), which was approved by Swissmedic on May 24, 2022.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.msd.ch\/en\/lyfnua-publication-of-clinical-trial-results\/","og_locale":"en_US","og_type":"article","og_title":"Lyfnua - Publication of clinical trial results - msd.ch","og_description":"Publication of clinical trial results for Lyfnua\u00ae (gefapixant), which was approved by Swissmedic on May 24, 2022.","og_url":"https:\/\/www.msd.ch\/en\/lyfnua-publication-of-clinical-trial-results\/","og_site_name":"msd.ch","article_modified_time":"2024-07-16T05:21:01+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.msd.ch\/en\/lyfnua-publication-of-clinical-trial-results\/","url":"https:\/\/www.msd.ch\/en\/lyfnua-publication-of-clinical-trial-results\/","name":"Lyfnua - Publication of clinical trial results - msd.ch","isPartOf":{"@id":"https:\/\/www.msd.ch\/en\/#website"},"datePublished":"2022-08-24T05:22:26+00:00","dateModified":"2024-07-16T05:21:01+00:00","description":"Publication of clinical trial results for Lyfnua\u00ae (gefapixant), which was approved by Swissmedic on May 24, 2022.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.msd.ch\/en\/lyfnua-publication-of-clinical-trial-results\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.msd.ch\/en\/#website","url":"https:\/\/www.msd.ch\/en\/","name":"msd.ch","description":"MSD researches and develops medicines and vaccines to save lives and improve patients' health. In Switzerland, 1000 employees in Lucerne and Zurich are dedicated to this.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.msd.ch\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.msd.ch\/en\/wp-json\/wp\/v2\/pages\/5880","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.msd.ch\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.msd.ch\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.msd.ch\/en\/wp-json\/wp\/v2\/users\/282"}],"replies":[{"embeddable":true,"href":"https:\/\/www.msd.ch\/en\/wp-json\/wp\/v2\/comments?post=5880"}],"version-history":[{"count":4,"href":"https:\/\/www.msd.ch\/en\/wp-json\/wp\/v2\/pages\/5880\/revisions"}],"predecessor-version":[{"id":8587,"href":"https:\/\/www.msd.ch\/en\/wp-json\/wp\/v2\/pages\/5880\/revisions\/8587"}],"wp:attachment":[{"href":"https:\/\/www.msd.ch\/en\/wp-json\/wp\/v2\/media?parent=5880"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}